New Injectable Drug Cuts Cholesterol 28% in Teens With Genetic High Cholesterol

Familial hypercholesterolemia affects 1 in 250 people, causing dangerously high cholesterol from birth and dramatically increasing heart disease risk. Early intervention is crucial, but current treatments require daily medication adherence that can be challenging for teenagers.

Researchers conducted a comprehensive two-year study of inclisiran, a novel RNA-based therapy that targets PCSK9, a protein regulating cholesterol production. The trial included 141 adolescents aged 12-18 across 51 sites in 26 countries, all with genetically confirmed familial hypercholesterolemia already on maximum statin therapy.

Participants received either inclisiran injections or placebo every three months initially, then every six months. Results were remarkable: inclisiran reduced LDL cholesterol by 28.5% compared to placebo at one year, with sustained 34% reductions at two years. The treatment was well-tolerated, with only mild injection site reactions in 16% of patients and no serious adverse events.

This represents a paradigm shift in pediatric cholesterol management. The infrequent dosing schedule could dramatically improve treatment adherence compared to daily medications, while the substantial cholesterol reductions may prevent early cardiovascular events. For longevity optimization, this highlights the critical importance of addressing genetic risk factors early in life.

However, long-term safety data in adolescents remains limited, and the treatment requires specialized medical supervision. The study population was predominantly white, limiting generalizability. While promising, inclisiran represents one tool in comprehensive cardiovascular risk reduction that must include lifestyle interventions.